Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617107 | 0.96 | LMNA (0.42) | LMNAENPP2TP53SMN1; SMN2HPGD | |
| SCHEMBL5617942 | 0.95 | ENPP2 (0.44) | LMNAENPP2TP53SMN1; SMN2HTT | |
| SCHEMBL5617904 | 0.93 | TP53 (0.41) | LMNAENPP2TP53SMN1; SMN2HPGD | |
| SCHEMBL5617263 | 0.88 | TNF (0.45) | LMNAENPP2TP53GAA | |
| SCHEMBL5616964 | 0.88 | TP53 (0.39) | LMNAENPP2TP53SMN1; SMN2HPGD | |
| SCHEMBL5617237 | 0.87 | FAAH (0.42) | LMNAENPP2TP53SMN1; SMN2HTT | |
| SCHEMBL5618891 | 0.87 | GAA (0.43) | LMNAENPP2TP53SMN1; SMN2HTT | |
| SCHEMBL3176214 | 0.87 | TLR7 (0.49) | LMNAENPP2TP53SMN1; SMN2HPGD | |
| SCHEMBL5616912 | 0.87 | ENPP2 (0.41) | LMNAENPP2TP53SMN1; SMN2HPGD | |
| SCHEMBL4324733 | 0.86 | ENPP2 (0.37) | LMNAENPP2TP53SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697873-B2 | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| EP-1730143-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094531-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | LMNA 4342/4885ENPP2 1117/4885TP53 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.